|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab, an anti-CD20 monoclonal antibody (mAb), is indicated in the treatment of B-cell non-Hodgkin lymphomas, chronic lymphoid leukemia, and rheumatoid arthritis.
|
30580638 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hodgkin's lymphoma (HL) has a unique immunophenotype derived from immunohistochemistry (positive for CD15, CD30, and Pax-5; negative for CD3, CD20 in most cases, and CD45).
|
30350336 |
2019 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD20 recombinant antibodies are among the most promising therapeutics for the treatment of B-cell malignancies such as non-Hodgkin lymphomas.
|
29178403 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.
|
29721381 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current findings can offer important implications to optimize the anti-CD20 strategies to treat B-cell non-Hodgkin lymphomas.
|
28805013 |
2018 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clonality detection rates in cHL improved as CD30-positive Reed-Sternberg (RS) cell density increased and CD20-positive B cell density decreased, although these correlations did not reach statistical significance.
|
22296097 |
2012 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD20 monoclonal antibodies (mAbs) have become the mainstay in the treatment of non-Hodgkin's lymphomas and have shown significant activity in patients with B-cell chronic lymphocytic leukemia.
|
21196171 |
2011 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-CD20 monoclonal antibody treatment has not only increased survival and cure rates in many non-Hodgkin lymphomas, but also has prompted an explosion in the development of novel antibodies and biologically active substances with specific cellular targets in the field of malignancies treatment.
|
20815894 |
2010 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anti-CD20 antibody rituximab has substantially improved outcomes in patients with B-cell non-Hodgkin lymphomas.
|
20139095 |
2010 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rituximab was approved initially by the US FDA and the European Medicines Agency for relapsed or refractory low-grade or follicular CD20+ B-cell non-Hodgkin lymphomas.
|
17338647 |
2007 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of CD20 on Reed-Sternberg cells could be demonstrated in 17% (7/42) of classic HL.
|
16084943 |
2005 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The recently identified lymphocyte-rich classical (lrc) HL is characterized by HRS cells with the immunophenotype of classical HRS cells (CD30(+)CD15(+)CD20(-)CD45(-)) but an infiltrate similar to lpHL and a clinical behavior resembling lpHL.
|
12670918 |
2003 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.
|
12411587 |
2002 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that the FcgammaRIIIa receptor 158V allotype displays a higher affinity for human immunoglobulin G1 and increased antibody-dependent cellular cytotoxicity, the aim of this study was to determine the influence of that FCGR3A polymorphism on the therapeutic response to rituximab, an anti-CD20 humanized immunoglobulin G1 increasingly used in the treatment of non-Hodgkin lymphomas.
|
11806974 |
2002 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A lymph node biopsy showed the histological features of HD (mixed cellularity) with infiltrating CD8+ lymphocytes, and immunohistochemical examination revealed the following phenotype of Reed-Sternberg cells: LeuM1/CD15+, BerH2/CD30+, L26/PanB-, UCHL-1/CD45RO-, cyCD3-, CD4, CD8-, CD20-, CD79a-, EMA-, EBER-1+, LMP-1+.
|
11372737 |
2001 |
|
Hodgkin Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The current case affords an opportunity to review the rarely reported expression of CD20 in T-cell neoplasms as well as the relationship between Hodgkin's disease and subsequently occurring non-Hodgkin's lymphomas.
|
11106083 |
2000 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, 96.9% of HD cases were negative for CD45, CD45-RO, CD43, and CD20.The four exceptions are discussed.All cases of HD were negative for EMA.
|
8639911 |
1996 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of this study provide support that a subset of HD represents a clonal B-cell neoplasm, and indicate that clonal IgH VDJ sequences are more frequently found in CD20+ HD.
|
7572792 |
1995 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Forty-nine H&RS cells (and 23 CD3+ or CD20+ lymphocytes as controls) from four patients with nodular sclerosing Hodgkin's disease (HD) and one patient each with lymphocyte predominant and mixed-cellularity HD were successfully analyzed by PCR.
|
8499644 |
1993 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This is in spite of the fact that RS cells expressing B-cell-associated antigen CD20 were detectable in 7/8 cases of LP HD and 6/24 cases of NS and MC HD with monoclonal antibody L26.
|
1632463 |
1992 |
|
Hodgkin Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distribution and phenotype of Epstein-Barr virus (EBV)-harboring cells were determined in Hodgkin's disease (HD) biopsies by in situ hybridization with [35S]-labeled RNA probes specific for the small EBV-encoded nuclear RNAs, EBER1 and EBER2, in some instances preceded by immunohistology for CD20, CD30, CD45RO, and CD68 antigens, the T-cell receptor beta-chain, and latent membrane antigen (LMP) of EBV.
|
1320954 |
1992 |